

Financial results *Full year 2024*

(preliminary)

Dr. Jean-Yves Parisot (CEO), Olaf Klinger (CFO)

30 January 2025



Agenda *Overview*





0 2024 at a glance

Financial highlights FY 2024

Strong recovery of profitability / Double-digit growth in bottom-line figures

Sales €4,999m (2023: €4,730m)	+8.7% organic growth +5.7% in reporting currency	Business Free Cash Flow¹ €680m 13.6% of sales	Capex €231m 4.6% of sales
EBITDA €1,033m +14.4% vs. FY 2023 ²	20.7% EBITDA margin (2023: 19.1% ²)	Net Income ³ €478m +40.5% vs. FY 2023 €3.42 Earnings per share	Net debt 2.3 x EBITDA (including pensions) €2,343m vs. 2,666m in 2023


¹ Business Free Cash Flow = EBITDA – CapEx (including cash effects from leasing) +/- changes in Working Capital

² Adjusted for one-time effects

³ Attributable to shareholders of Symrise AG

Sales 2024 *Strong organic growth*





Sales by Segment 2024 *Both Segments with high organic growth rates*



Taste, Nutrition & Health in €m / organic growth in % 3,091 2,978 2023



+3.8 %*

Growth driven by Food & Beverages and Pet Food





+8.9 %*

Fragrance with continued high growth momentum, Significant recovery of Aroma Molecules


Sales by Region in 2024

Double-digit organic growth in Latin America and EAME

Organic growth by region in %



Sales by region % of global sales




Strong financial track record *Successful EBITDA turnaround in 2024*



Growth and profitability since IPO

Sales and EBITDA in €m




¹ Adjusted for transaction and integration costs as well as one-off valuation effects related to business combinations. 2016 and 2019 restated for finalized purchase price allocations | ² Without impairment of associated company Swedencare | ³ Normalized for one-time effects |

02 Financials in detail


Group 2024 *Organic growth of 8.7% (reported 5.7%)*

Sales development FY 2024

In €m



Sales development Q4 2024



Organic growth of **8.7%** in 2024; Without the impact of hyperinflation, organic growth of **8.1%** in 2024

Negative sales contribution in FY 2024 from portfolio effect of €38m: Divestment of 51 % of Trading Business in UK, as of March 1, 2024.

Negative currency effects of €104m in 2024, attributable to multiple currencies.

Q4 2024 is showing **organic growth** of **5.9%** without negative influence from Hyperinflation.

Negative sales contribution from **portfolio effect of €10m** as mentioned above

Positive impact from FX due to Hyperinflation effect from Argentina



Group profitability 2024 *EBITDA increase of +160bps to 20.7%*

in€ million		FY 2023	FY 2023 ¹	FY 2024	Change in %
Sales		4,730	4,730	4,999	5.7
Gross profit		1,693	1,739	1,963	12.9
Gross profit margin	in %	35.8	36.8	39.3	250bps
EBITDA		852	903	1,033	14.4
EBITDA margin	in %	18.0	19.1	20.7	160bps
Depreciation		176	176	205	16.6
Amortization		116	116	110	-5.2
EBIT		559	611	718	17.4
EBIT margin	in %	11.8	12.9	14.4	150bps



Double digit growth of Gross profit, EBITDA and EBIT

EBITDA margin increased to 20.7 %, which is 160 bps above previous year's adjusted EBITDA margin¹.

Higher Depreciation in 2024:

Due to increased CAPEX; impacted by impairment on plants and machinery in Pet Food and Aqua


¹ Adjusted for one-time effects (€52m)

Symrise efficiency program *Total savings of €50m in FY 2024 achieved*

2024 dedicated initiatives

- Implemented a cost-conscious culture
- Executed hiring freeze
- Thorough **use of saving potential**, e.g.
 - Travel efficiency & effectiveness
 - Focused consultancy initiatives

- Implemented a of group-wide tracking dashboard
- Detailed cost tracking on a regular basis



First lasting efficiencies out of ONE SYM program

- Consolidation of expertise
- Leverage existing know-how with a **new lean mindset**

- Process alignment and reorganization
- Harmonization & bundling of activities


Thereof €28m in TN&H, €18m in S&C and €4m in Corporate.

Taste, Nutrition & Health FY 2024

Healthy growth and strong profitability

Sales development

ln €m



Short P&L

In €m

in € million		FY 2023¹	FY 2024	Change in %
EBITDA		626.8	686.4	9.5
EBITDA margin	in %	21.0	22.2	
EBIT		426.4	463.5	8.7
EBIT margin	in %	14.3	15.0	

Organic growth of 7.8 % resulting from both divisions.

- **Food & Beverage** continued to develop very positively with high single digit growth, driven by Savory, Sweet and Beverages. Negative Portfolio effect from divestment of Trading Business, UK.
- **Pet Food** with positive growth momentum. Good sales development in Pet Palatability showing a high single digit growth rate. Pet Nutrition with negative growth due to challenging market conditions in EAME as well as North America.

EBITDA margin increased to 22.2 % (2023: 21.0 $\%^1$).


¹Adjusted for income from an insurance reimbursement for a cybersecurity incident in 2020 of €2.4m

Scent & Care FY 2024

Double-digit growth with strong business in Fragrance

Sales development

In €m



Short P&L

In €m

in € million		FY 2023¹	FY 2024	Change in %
EBITDA		276.7	347.0	25.4
EBITDA margin	in %	15.8	18.2	
EBIT		184.8	254.4	37.7
EBIT margin	in %	10.5	13.3	


Organic growth of 10.2 % resulting from all divisions:

- Fragrance enjoyed double-digit sales growth in Consumer Fragrances as well as high single digit growth in Fine Fragrances.
- Aroma Molecules sales development recovered significantly in FY 2024 due to resumption of production in Colonels Island.
- Cosmetic Ingredients posted high single-digit growth driven by strong demand in Micro Protection and Active & Botanicals.

EBITDA margin amounts to 18.2 % (2023¹: 15.8 %).

¹ Adjusted for one-time effects in connection with the production stoppage at the Colonels Island site, the reorganization following the segments' realignment and cost associated with the antitrust investigations and for income from an insurance reimbursement for a cybersecurity incident in 2020 (total one-time effects in 2023: €54.2m)

EPS *Increase of 40.5 % to €3.42*






Financial result: improved by €22m, mainly due to lower interest expenses in connection with financing as well as interest on pension provisions and lower net losses from hyperinflation-related adjustments).


Income tax: rate at 25.4 % within the tax guidance of 25-27 %.

Net income: €138m above previous year mainly due to strong operating results.EPS: increased by 40.5 % to €3.42 per share.

Working capital and Capex

Clearly defined actions and measures to reach mid-term targets





Measures:

- Increase in Working Capital mainly driven from growth in trade receivables in line with sales growth. Slight increase in inventories.
- Working Capital remains focus area with tightened management of payment terms as well as overdues and increased efforts on reducing inventories.


Investments:

- Important S&C projects on track. Lower spendings in TN&H projects due to delayed authority permits, where we are closely aligning our investments to market needs.
- Investments into capacity expansion and new technologies are closely monitored, as part of driving efficiency.
- Increased investments in IT to drive **digitalization**.



Business Free Cash Flow (BFCF) *Strong improvement with BFCF of 13.6 %*





FY 2024 BFCF of €680m = 13.6% of sales significantly improved vs. PY (FY 2023¹: €553m = 11.7% of sales)

Strong operating performance

Slight decrease in **CAPEX from €270m** in FY 2023 **to €231m** in FY 2024.

Improvement of working capital continued to be in focus.

Ambition 2025 *BFCF around 14 % of sales; mid term target above 14%*

EBITDA (adjusted)

- Investments (including cash effects from leasing)

-/+ Changes in working capital


= Business Free Cash Flow

¹FY 2023 BFCF adjusted for one-time effects

Net debt development



Reduction of net debt incl. pensions leads to leverage of 2.3 x EBITDA



Net debt (incl. pension provisions and leasing obligations) /EBITDA ratio

Net debt/EBITDA ratio

Status Quo

Acquisitions of

Net debt including pension provisions and leasing obligation of €2,343m reflects 2.3 x EBITDA.

Net debt of €1,836m (2023: €2,166m) reflects 1.8 x EBITDA.

Ambition

Long-term target of 2.0 to 2.5 x EBITDA (incl. pensions provisions and leasing obligation).

Unchanged since IPO.

Priority: Remain investment grade profile.

03 Market trends, Strategy, Outlook

S!

when making a purchase decision

Key market trends Well-aligned business portfolio and product offering driven by key megatrends

Humans






- Preeminence of social media influencers

• Prioritized holistic well-being and preventive health

Our transformational journey towards a sustainable performance *Being and staying unique*




Unleashing the full beauty of ONE Symrise

- The power of ONE Symrise: creating more value for all our stakeholders, and ultimately improving our financial performance
- The power of ONE innovation ecosystem: a unique set-up for co-building differentiated offers for our customers, with "ONE CARE" as a profitable growth accelerator

> The power of ONE Sym:

a transformation program to deliver the 'ONE Symrise Strategy' based on excellence in operations based on a performance driven mindset

Cross-fertilizing for a unique "ONE CARE" Leveraging synergies between S&C and TN&H



vet trends in

Key product trends in holistic health, well-being & beauty

Move from **supplements** to **functional food**

Appearance of a **next generation** of nutritional solutions and supplements for **healthy aging**

More and more blurry borders between beauty topicals and health attributes, like "beauty from within"

- Focus on high potential, high-growth, high-margin accretive activities
- Join forces of our Cosmetic Ingredients and Health active ingredients, creating new product solutions
- Continue to invest in "white" biotechnology" platform to extend portfolio

Outlook 2025 *Confident to achieve ambitious targets*



Organic growthProfitability
EBITDA marginBusiness Free Cash Flow
% of salesImage: Image: Image:

Corporate view Business environment fully intact with high industry dynamics

Taste, Nutrition & Health Building competencies towards complementary business areas

Scent & Care Strong capabilities in fragrances and cosmetic ingredients

Execution of an efficiency program Aiming for higher profitability

Mid-term financial objectives

Symrise specifies 2028 financial targets



Financial targets	Mid-term until 2028
Organic sales growth (CAGR)	5 – 7%
EBITDA margin	21 – 23%
Business Free Cash Flow	>14%

Contribution from M&A as an additional topline driver

Focus on opportunities that add value in terms of products, technologies and end-markets

We are well positioned...

...to achieve our short-, mid- and long-term targets



Well positioned to deliver on our financial targets



always inspiring more

Symrise AG

Financial calendar 2025

Company report 2024

29 April Q1 Trading statement

20 Mai Annual general meeting **30 July** H1 2025 Financial results

28 October 9M 2025 Trading statement

This document contains forward-looking statements, which are based on the current estimates and assumptions by the corporate management of Symrise AG. Future performance and the results actually achieved by Symrise AG and its affiliated companies depend on a number of risks and uncertainties and may therefore differ materially from the forward-looking statements. Many of these factors are outside Symrise's control and cannot be accurately estimated in advance, such as the future economic environment and the actions of competitors and others involved in the marketplace. Symrise neither plans nor undertakes to update any forward-looking statements.



Contact

 $\circ \approx$

37603 Holzminden, Germany

Rene Weinberg Investor Relations rene.weinberg@symrise.com

Bernhard Kott Corporate Communications bernhard.kott@symrise.com






Back-up

Hyperinflation impact on organic growth



One-off effect on Q4 organic growth by conversion into reporting currency



- According to IAS29, hyperinflation accounting (e.g. applying closing rate instead of average rate) must be applied when the cumulative inflation over three years is around 100% or more
- Currently applied to Argentina, Venezuela and Turkey

¹Excluding hyperinflation impact

- **Q4 calculated as residual** of FY 2024 and YTD Sep24 which are **converted based on closing rates** of respective prior year periods (as per IAS29)
- Depreciation of ARS between Sep-23 and Dec-23 results in a **negative impact based on conversion into EUR**
- With reference to IAS29, Symrise decided to cap its organic growth from hyperinflation countries at 26% (annually) and defined the remainder as hyperinflation pricing/impact
- Additionally, there is a seasonality effect in Q4